Genelux (GNLX) Asset Utilization Ratio (2023 - 2024)
Genelux's (GNLX) quarterly Asset Utilization Ratio came in at 0.0 in Q4 2024, down 96.11% year-on-year from 0.01 in Q1 2024, and up 13.95% quarter-over-quarter from 0.0 in Q3 2024.
Genelux (GNLX) Asset Utilization Ratio (2023 - 2024) Analysis & Trends
Genelux's Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.0 for Q4 2024.
- On a quarterly basis, Asset Utilization Ratio fell 96.11% year-over-year to 0.0 in Q4 2024; TTM through Dec 2024 was 0.0, a 96.11% decrease from a year earlier, with the FY2025 full-year figure at 0.0, up 16.5% from the prior year.
- Asset Utilization Ratio grew to 0.0 in Q4 2024 per GNLX's latest filing, from 0.0 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.01 in Q4 2023 and bottomed at 0.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 0.69 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.01 |